Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). This study was undertaken to evaluate the risk of major adverse cardiovascular events (MACE) in patients with RA receiving tofacitinib. METHODS: Data were pooled from patients with moderately to severely...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis Rheumatol
Hauptverfasser: Charles‐Schoeman, Christina, DeMasi, Ryan, Valdez, Hernan, Soma, Koshika, Hwang, Lie‐Ju, Boy, Mary G., Biswas, Pinaki, McInnes, Iain B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Rheumatoid Arthritis
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6754249/
https://ncbi.nlm.nih.gov/pubmed/31385441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40911
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge